跳至主要内容
临床试验/NCT00268320
NCT00268320已完成不适用

Clinical Investigation of the Medtronic Concerto™ Cardiac Resynchronization Therapy (CRT) and Implantable Cardioverter Defibrillator (ICD) Therapies (CRT+ICD Device)

Medtronic Cardiac Rhythm and Heart Failure51 个研究点 分布在 11 个国家目标入组 270 人开始时间: 2006年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
270
试验地点
51
主要终点
Complication rate

研究概览

简要总结

Heart failure is a progressive disease that decreases the pumping action of the heart. This may cause a backup of fluid in the heart and may result in heart beat changes. When there are changes in the heart beat sometimes an implantable heart device is used to control the rate and rhythm of the heart beat. In certain heart failure cases, when the two lower chambers of the heart no longer beat in a coordinated manner, cardiac resynchronization therapy may be prescribed.

People who have a dangerously fast heart beat, or whose heart is at risk of stopping beating, may be in need of an electronic device called an implantable cardioverter defibrillator (ICD).

Atrial tachyarrhythmia (AT) is the name for rapid beats in the upper chambers of the heart. People with AT may experience symptoms such as heart palpitations (a racing or pounding feeling in the chest), shortness of breath, dizziness, fatigue or weakness.

The purpose of this study is to study an investigational implantable device containing Cardiac Resynchronization Therapy (CRT) and Implantable Cardioverter Defibrillator (ICD) therapies (CRT+ICD device) in subjects who are at significant risk of developing atrial tachyarrhythmias.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects who require the implantation of an Implantable Cardioverter Defibrillator
  • Subjects who have heart failure that severely limits daily activities (NYHA Class III) or Subjects who have severe heart failure and should always be resting (NYHA Class IV)
  • Subjects with reduced heart pumping function (left ventricular ejection fraction ≤ 35%)

排除标准

  • Subjects who have constant atrial fibrillation (top chambers of the heart beat too fast continuously)
  • Subjects who are post-heart transplant

结局指标

主要结局

Complication rate

Atrial defibrillation effectiveness

次要结局

  • Change in patient health status during the study
  • System performance
  • Adverse events

研究者

发起方
Medtronic Cardiac Rhythm and Heart Failure
申办方类型
Industry

研究点 (51)

Loading locations...

相似试验